08:55 AM EDT, 06/17/2024 (MT Newswires) -- Health care stocks were declining premarket Monday with the Health Care Select Sector SPDR Fund (XLV) retreating 0.3% and the iShares Biotechnology ETF (IBB) down 0.5%.

Nurix Therapeutics ( NRIX ) shares were up more than 5% after the company said an ongoing phase 1a/b clinical trial of its drug NX-5948 is yielding what one of its researchers called "impressive" results for the treatment of adult patients with relapsed or refractory B-cell malignant cancers such as non-Hodgkin lymphoma.